RAIN

Rain Oncology Inc

NASDAQ

Add Alert

RAIN

Rain Oncology Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Milesblue42 Free

12/19/23 2:17 PM

Post #42

BRODSKY & SMITH SHAREHOLDER UPDATE:

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE -- AYX), Rain Oncology, Inc. (Nasdaq -- RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq -- CERE)

BALA CYNWYD, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky @bulldop01Toror-4847. There is no cost or financial obligation to you.

Alteryx, Inc. (NYSE -- AYX)

Under the terms of the agreement, Alteryx will be acquired by Clearlake Capital Group, L.P. ("Clearlake") and Insight Partners ("Insight," and together with Clearlake, the "Buyers"). Alteryx stockholders will receive $48.25 per share in cash for each share of Alteryx Class A or Class B common stock that they own. The investigation concerns whether the Alteryx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Buyers are paying fair value to shareholders of the Company.

https://www.marketwatch.com/press-release/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-alteryx-inc-nyse-ayx-rain-oncology-inc-nasdaq-rain-consolidated-communications-holdings-inc-nasdaq-cnsl-cerevel-therapeutics-holdings-inc-nasdaq-cere-c0309f5f?mod=mw_quote_news_seemore

https://www.brodskysmith.com/cases/alteryx-inc-nyse-ayx/.

axelvento

12/14/23 12:28 AM

Post #41

Re: #40: @PennyWorld - Not sure I understand your point. $1.16

it will still be on the market?
this is the question

PennyWorld PremiumMember

12/14/23 12:02 AM

Post #40

Re: #39: @axelvento - so what? Pathos has established a separate, wholly-owned

Not sure I understand your point. $1.16 is $1.16. Good for some SH.

For me, now I have to swing trade this at a higher range. Buy at 1.10, take profits at s 1.16

axelvento

12/13/23 11:31 PM

Post #39

Re: #38: @Milesblue42 - NEW PR RAIN being bought out

so what? Pathos has established a separate, wholly-owned subsidiary to complete the Transaction. Following the tender offer closing, this subsidiary will be merged into Rain with Rain as the surviving entity of the merger, which will then operate as a separate, wholly-owned subsidiary of Pathos. If the tender offer is successful, the Transaction is expected to close in January 2024.

Milesblue42 Free

12/13/23 6:25 PM

Post #38

NEW PR RAIN being bought out

https://www.marketwatch.com/press-release/rain-oncology-enters-into-agreement-to-be-acquired-by-pathos-ai-for-1-16-in-cash-per-share-plus-contingent-value-rights-06ce1004?mod=mw_quote_news_seemore

Press Release
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

Milesblue42 Free

12/13/23 6:11 PM

Post #37

Was there a Trading Halt? Or Rumor??

PennyWorld PremiumMember

12/13/23 5:23 PM

Post #36

Re: #35: @Milesblue42 - Are We getting......Close??

I don't think so. I suspect we'll see another pull back. Profit taking.

Milesblue42 Free

12/13/23 3:21 PM

Post #35

Are We getting......Close??

Monksdream PremiumMember

09/11/23 2:04 PM

Post #34

RAIN new 52 week low

Jeritron5100 Free

06/08/23 6:20 PM

Post #33

Range is tightening. Big move coming soon

Jeritron5100 Free

06/07/23 4:49 PM

Post #32

Held 1.23 strong today then a nice late run to 1.30. I like where this is headed. If this first breaks 1.33 and then ultimately 1.37 next leg up will be huge.

axelvento

06/07/23 12:02 AM

Post #31

Re: #21: @WARHAMMER - RAIN - being accumulated-- when "they" are done--

$RAIN 3.42 in cash per share = MULTIBAGGER$

axelvento

06/06/23 11:47 PM

Post #30

just waiting for news from Tang. Price will stay in this channel until he is done loading or news breaks on a take over bid.

axelvento

06/06/23 11:29 PM

Post #29

Re: #26: @PennyWorld - Reason for PPS crash... failure to meet FDA

I don’t see why this man would invest millions & not do nothing. He did a takeover bid in JNCE 3 months ago with fire results for shareholders. Expecting a pop here very soon

axelvento

06/06/23 11:25 PM

Post #28

Re: #26: @PennyWorld - Reason for PPS crash... failure to meet FDA

last arrived-great signal: https://fintel.io/so/us/rain/tang-capital-partners-lp

deep hands.

Sauerkraut Free

06/05/23 1:20 PM

Post #27

Re: #22: @PennyWorld - What caused the price to crash in May?

Bad P3 Trial anouncmet. But not that bad, still better than everything else in that sector of care.....imo

PennyWorld PremiumMember

06/05/23 1:15 PM

Post #26

Reason for PPS crash... failure to meet FDA Phase 3 primary endpoint for MANTRA.
https://finance.yahoo.com/news/rain-oncology-announces-topline-results-120000095.html?.tsrc=rss

However, RAIN does have two other drugs in the pipeline, but unfortunately neither one are in Phase 3 trials.
Pipeline....
https://www.rainoncology.com/pipeline

Fundamentals (debt to equity, O/S, etc) are great, and I see no historical record of an R/S.

IMO RAIN is oversold, but the panic selling may not be complete. It should see a gradual (slow) recovery to the upside over time. But without positive news on the FDA front, I see these price levels as setting a new support level for quite some time.

JMHO

WARHAMMER

06/05/23 11:02 AM

Post #25

Re: #24: @PennyWorld - Why? Could be a falling knife.

Knife fell, time to look forward.

PennyWorld PremiumMember

06/05/23 10:54 AM

Post #24

Re: #23: @WARHAMMER - Who cares. :)

Why? Could be a falling knife.

WARHAMMER

06/05/23 10:51 AM

Post #23

Re: #22: @PennyWorld - What caused the price to crash in May?

Who cares. :)

PennyWorld PremiumMember

06/05/23 10:50 AM

Post #22

Re: #21: @WARHAMMER - RAIN - being accumulated-- when "they" are done--

What caused the price to crash in May?

WARHAMMER

06/05/23 10:18 AM

Post #21

RAIN - being accumulated-- when "they" are done-- its gonna fly hard

axelvento

06/04/23 12:09 AM

Post #20

Tang bought 30% of the float...

Sauerkraut Free

06/02/23 1:20 PM

Post #19

Re: #18: @Sauerkraut - Fore sure, I agree. But I'm not here

Let's go

Sauerkraut Free

06/02/23 1:19 PM

Post #18

Re: #17: @TheFinalCD - TRADING HALF THE FLOAT AND NOT MUCH MOVEMENT

Fore sure, I agree. But I'm not here to protect retail......imo

TheFinalCD PremiumMember

06/02/23 1:17 PM

Post #17

Re: #16: @Sauerkraut - Let's go. $2.5+

TRADING HALF THE FLOAT AND NOT MUCH MOVEMENT IS CRIMINAL

LOL

Sauerkraut Free

06/02/23 10:52 AM

Post #16

Let's go. $2.5+

axelvento

06/02/23 12:58 AM

Post #15

Planned MANTRA-2 clinical update at a medical conference in 4Q 2023

PHASE 2- it works very well

Milademetan Shows Early Activity in MDM2-Amplified Advanced Solid Tumors

Notably, activity with the MDM2 inhibitor was observed in patients with heavily pretreated, refractory disease.

axelvento

06/02/23 12:47 AM

Post #14

more news to come:

Evaluate avenues to enhance the pipeline through precision oncology program acquisition-

axelvento

06/02/23 12:44 AM

Post #13

$RAIN 36.4 million shares of common stock outstanding
Year-end 2023 cash guidance of $75-$80 million, and cash runway to year-end 2026

axelvento

06/02/23 12:36 AM

Post #12

There's one piece left-- Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -

At the data cutoff of October 26, 2022, 17 patients were enrolled. Two unconfirmed partial responses were observed in patients with pancreatic and lung cancer with a tumor regression of 34% and 30% with lung cancer, respectively. Additionally, there was promising tumor regression of 29% in a patient with biliary tract cancer and 27% in a patient with breast cancer; both are receiving continued investigational therapy.

https://www.rainoncology.com/news-press-releases/rain-therapeutics-provides-interim-analysis-of-phase-2-basket-trial-of-milademetan-for-mdm2-amplified-advanced-solid-tumors-mantra-2

axelvento

06/02/23 12:32 AM

Post #11

NEW$$$$-Tang Capital Partners Lp ownership in RAIN / Rain Oncology Inc
2023-06-01 - Tang Capital Partners Lp has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,740,341 shares of Rain Oncology Inc (US:RAIN). This represents 14.1 percent ownership of the company.

https://fintel.io/so/us/rain/tang-capital-partners-lp